NKE
30
2
V
56
2
CA
16
3
IRM
68
5
AKAM
54
3
AAP
30
3
APH
65
4
L
51
5
RCL
81
4
ROP
53
2
FIS
46
-9
DTE
49
2
WEC
45
4
CHD
45
3
O
33
-4
NVDA
55
4
DUK
37
2
HP
41
5
JBHT
63
3
JNPR
59
3
NKE
30
2
V
56
2
CA
16
3
IRM
68
5
AKAM
54
3
AAP
30
3
APH
65
4
L
51
5
RCL
81
4
ROP
53
2
FIS
46
-9
DTE
49
2
WEC
45
4
CHD
45
3
O
33
-4
NVDA
55
4
DUK
37
2
HP
41
5
JBHT
63
3
JNPR
59
3
Financhill
Back

Perspective Therapeutics 10K Form

Sell
30

CATX
Perspective Therapeutics

Last Price:
12.34
Seasonality Move:
26.28%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CATX News And Ratings

See the #1 stock for the next 7 days that we like better than CATX

CATX Financial Statistics

Sales & Book Value

Annual Sales: $3.55M
Cash Flow: $-9.92M
Price / Cash Flow: 0
Annual Sales: $5.06
Price / Book: 2.44

Profitability

EPS (TTM): -1.68000
Net Income (TTM): $-59.02M
Gross Margin: $817K
Return on Equity: 0%
Return on Assets: 0%

Perspective Therapeutics Earnings Forecast

Key Perspective Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 29 years for CATX is 23.00%.
  • The Selling, General & Administrative Expenses for CATX have been equal to 200.08% of Gross Profit Margin.
  • The Interest Expense is -0.18% of Operating Income.
  • Per Share Earnings over the last 30 years have been positive in 16 years.

Perspective Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: CATX
Website: perspectivetherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CATX Technical Analysis vs Fundamental Analysis

Sell
30
Perspective Therapeutics (CATX) is a Sell

Is Perspective Therapeutics a Buy or a Sell?